In brief
Stéphane Bancel argues that Moderna's mRNA technology is a true platform. Once the first drug works, later drugs mostly mean changing the sequence of genetic letters. He says this lowers risk and manufacturing cost compared with conventional drugs. He also argues that culture, speed of learning and hard early safety work protect the company better than patents or publicity.
The tension is between an unproven idea and the money and trust it needed. Moderna raised huge sums and said little publicly, which drew comparisons to Theranos. Bancel says he stayed quiet on purpose, so a big drugmaker could not crush the company, and he shows how his Lilly, bioMérieux and Silicon Valley experience shaped his choices, including mistakes like the failed 'ventures' structure.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
Host Luke Timmerman says Moderna Therapeutics attracted about $2 billion from investors and partners over eight years, much of it before human data.
“Moderna has been able to convince enough investors and partners to throw $2 billion behind its efforts over the last eight years to create this new modality of treatment.”
0:01:30 · Luke Timmerman · Funding · 2018
Stéphane Bancel says Moderna put six new drugs into clinical trials in 2017, bringing its total to 10 in the clinic.
“We put six new drugs in clinical trial. So today we have 10 drugs in clinical trial, which is a great number”
0:05:17 · Stéphane Bancel · Clinical pipeline · 2017
Bancel says Moderna's first successful phase one therapeutic trial was a VEGF program for the heart run with AstraZeneca, meeting its primary and secondary endpoints.
“We had our first phase one for therapeutics that was successful with AstraZeneca for VEGF in the heart, met primary, secondary endpoint.”
0:05:50 · Stéphane Bancel · Clinical results · 2017
After a master's in biochemical engineering at Minnesota, Stéphane Bancel moved to Tokyo and lived there for almost four years working for bioMérieux.
“And so I went from Minnesota straight to Tokyo. And I lived in Tokyo for almost four years.”
0:10:18 · Stéphane Bancel · Early career · 1990s
Stéphane Bancel graduated from Harvard Business School in May 2000, when the Nasdaq peaked, and then joined Eli Lilly instead of a dot-com company.
“I graduated in May 2000 which as you know is when the Nasdaq peaked”
0:13:29 · Stéphane Bancel · Education · 2000
Bancel says an FDA warning letter on Eli Lilly's injectable insulin manufacturing site held up Lilly's planned biologic launches, because those products were to be made in the same plant.
“because there was a warning letter on the injectable site that was making insulin, all the biologics needed to be injected as well.”
0:18:06 · Stéphane Bancel · FDA manufacturing · 2000s
As Eli Lilly's country manager for Belgium, Stéphane Bancel helped launch Alimta, Cymbalta and Cialis.
“we launched new products like Alimta for cancer, Cymbalta for CNS. We launched Cialis which was a really fun product to launch”
0:19:53 · Stéphane Bancel · Drug launches · 2000s
Stéphane Bancel was 32 when Alain Mérieux first raised the idea of him becoming CEO of bioMérieux.
“of course you are way too young to have a chance I was 32 at the time to have a chance”
0:20:47 · Stéphane Bancel · bioMérieux CEO · 2000s
Bancel says bioMérieux operated in 42 countries, with about 10 plants and 10 or 11 labs, while he was CEO.
“We had presence in 42 countries. So we had teams in 42 countries. I think 10 plants around the world, 10 or 11 labs around the world.”
0:24:03 · Stéphane Bancel · bioMérieux scale · 2000s
The experiment Nubar Afeyan showed Bancel, from a Harvard lab, involved injecting mRNA encoding a human protein into mouse muscle and finding the human protein in the mouse's blood.
“showing that they had injected, you know, mRNA-encoded human hippo in a mouse muscle.”
0:28:13 · Stéphane Bancel · mRNA origin · 2010
Bancel says about two-thirds of human proteins act inside cells and only about a third enter the bloodstream, which was the part biotech drugs had mainly reached.
“around two-thirds of a human protein, a proteome, are intracellular protein. It's only a third that goes into the bloodstream”
0:30:27 · Stéphane Bancel · Proteome
Moderna began full operations, scaling up and hiring in the summer of 2011.
“we started truly operations and scaling up and hiring people in the summer of 2011.”
0:36:46 · Stéphane Bancel · Company founding · 2011
Bancel had Moderna test two drugs in monkeys at once so that investors and pharma partners could not dismiss a single success as luck.
“we tried two drugs in Monkey at the same time because I told myself if we do only one, everybody is going to tell me”
0:37:18 · Stéphane Bancel · Preclinical safety · 2012
Bancel set Moderna's early team a goal of making 100 different proteins in mice, a number he says he picked arbitrarily.
“I asked them to do 100 different proteins in mice.”
0:37:56 · Stéphane Bancel · Early experiments · 2012
Luke Timmerman says Moderna's deal with AstraZeneca included $240 million up front for mRNA drugs across about 40 indications.
“AstraZeneca, $240 million up front to develop mRNAs against something like 40 different indications, cardiovascular, metabolic, and a couple of other things.”
0:35:57 · Luke Timmerman · AstraZeneca deal · 2013
Bancel says he first met AstraZeneca CEO Pascal Soriot at a three-hour breakfast in December 2012 during the partnership talks.
“he set up a breakfast in Gettysburg with Pascal in December of 2012. And so I met Pascal for the first time.”
0:46:16 · Stéphane Bancel · AstraZeneca deal · 2012
Bancel says Moderna's first financing rounds before the AstraZeneca deal were $2 million, $2 million, $7 million and $25 million.
“The first round of Moderna, everybody forgets, was $2 million. The A of Moderna was $2 million. The B was $7 million. And the C was $25 million.”
0:50:36 · Stéphane Bancel · Early funding · 2011
Bancel says Moderna's AstraZeneca deal happened in March 2013, after which the company chose to raise additional money.
“after the AZ deal, which happened in March 13, we decided to raise more money”
0:54:26 · Stéphane Bancel · AstraZeneca deal · 2013
Bancel says Moderna's cash grew from about $20 million in March 2013 to about $500 million by mid-January 2014.
“we went from March 1st of 2013 with literally $20 million in the bank to January 15th JP Morgan 2014 $500 million in the bank”
0:54:26 · Stéphane Bancel · Moderna finances · 2013
Moderna folded its separate venture teams back into a single company in the summer of 2017, after learning that they weakened the link between platform and biology discovery.
“we explained when we unfolded them last summer, in summer of 17, end of the summer, is we've learned that because the platform is still so raw”
0:55:53 · Stéphane Bancel · Corporate structure · 2017
Bancel says Moderna spends roughly $100 million per year on its core platform, including process innovation and formulation.
“We need to fund the platform, give or take 100 million bucks per year.”
0:57:21 · Stéphane Bancel · Platform spending · 2017
Bancel says that when he surveyed Silicon Valley companies about onboarding, Netflix's took two hours while Facebook's took five weeks.
“from Netflix where the onboarding was two hours where you had Facebook where it was five weeks”
1:02:54 · Stéphane Bancel · Onboarding · 2014
Bancel says Moderna was building a highly automated manufacturing plant in Norwood, Massachusetts, a $125 million investment.
“it's a $125 million investment in Norwood in the 10 miles south of Boston it's going”
1:04:36 · Stéphane Bancel · Manufacturing plant · 2018